Transfusion-Transmitted Cytomegalovirus: Lessons From a Murine Model

Transfusion Medicine Reviews

Volumn 21, Issue 1, 2007, Pages 26-36

  Roback, John D ^a   Su, Leon ^a   Zimring, James C ^a   Hillyer, Christopher D ^a  

^a Department of Pathology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL ACTIVITY; BLOOD DONOR; BLOOD TRANSFUSION; CELL TYPE; CYTOMEGALOVIRUS INFECTION; HUMAN; HUMAN CYTOMEGALOVIRUS; IMMUNOASSAY; INFECTION RISK; MONOCYTE; MORBIDITY; MORTALITY; RECIPIENT; REVIEW; STIMULATION; TORQUE TENO VIRUS; VALIDATION PROCESS; VIRUS LATENCY; VIRUS REACTIVATION; VIRUS TRANSMISSION;

ANIMALS; BLOOD COMPONENT TRANSFUSION; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DISEASE MODELS, ANIMAL; HUMANS; MICE; MONOCYTES; SIGNAL TRANSDUCTION; VIRUS ACTIVATION; VIRUS LATENCY;

EID: 33845317247     PISSN: 08877963     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tmrv.2006.08.005     Document Type: Review

References (79)

1. Pass R.F. Cytomegalovirus. Fields's virology (2001), Lippincott-Williams and Wilkins, Philadelphia 2675-2705
2. Roback J.D. Human herpesvirus infections. Blood banking and transfusion medicine: Basic principles & practice (2003), Churchill Livingstone, Philadelphia 465-485
3. Kreel I., Zaroff L.I., Canter J.W., et al. A syndrome following total body perfusion. Surg Gynecol Obstet 111 (1960) 317-321
4. Smith D. A syndrome resembling infectious mononucleosis after open-heart surgery. Br Med J 1 (1964) 945-948
5. Alfieri C., Tanner J., Carpentier L., et al. Epstein-Barr virus transmission from a blood donor to an organ transplant recipient with recovery of the same virus strain from the recipient's blood and oropharynx. Blood 87 (1996) 812-817
6. Dollard S.C., Nelson K.E., Ness P.M., et al. Possible transmission of human herpesvirus-8 by blood transfusion in a historical United States cohort. [see comment]. Transfusion 45 (2005) 500-503
7. Hillyer C.D., Snydman D.R., and Berkman E.M. The risk of cytomegalovirus infection in solid organ and bone marrow transplant recipients: Transfusion of blood products. Transfusion 30 (1990) 659-666
8. Hillyer C.D., Lankford K.V., Roback J.D., et al. Transfusion of the HIV seropositive patient: Immunomodulation, viral reactivation, and limiting exposure to EBV (HHV-4), CMV (HHV-5) and HHV-6, 7, and 8. Transfus Med Rev 13 (1999) 1-17
9. Preiksaitis J.K. Indications for the use of cytomegalovirus-seronegative blood products. Transfus Med Rev 5 (1991) 1-17
10. Roback J.D. CMV and blood transfusions. Rev Med Virol 12 (2002) 211-219
11. Yeager A.S., Grumet F.C., Hafleigh E.B., et al. Prevention of transfusion-acquired cytomegalovirus infections in newborn infants. J Pediatr 98 (1981) 281-287
12. Bowden R.A., Sayers M., Flournoy N., et al. Cytomegalovirus immune globulin and seronegative blood products to prevent primary cytomegalovirus infection after marrow transplantation. N Engl J Med 314 (1986) 1006-1010
13. Bowden R.A., Slichter S.J., Sayers M.H., et al. Use of leukocyte-depleted platelets and cytomegalovirus-seronegative red blood cells for prevention of primary cytomegalovirus infection after marrow transplant. Blood 78 (1991) 246-250
14. Miller W.J., McCullough J., Balfour Jr. H.H., et al. Prevention of cytomegalovirus infection following bone marrow transplantation: A randomized trial of blood product screening. Bone Marrow Transplant 7 (1991) 227-234
15. Wilhelm J.A., Matter L., and Schopfer K. The risk of transmitting cytomegalovirus to patients receiving blood transfusions. J Infect Dis 154 (1986) 169-171
16. Preiksaitis J.K., Brown L., and McKenzie M. The risk of cytomegalovirus infection in seronegative transfusion recipients not receiving exogenous immunosuppression. J Infect Dis 157 (1988) 523-529
17. Preiksaitis J.K., Desai S., Vaudry W., et al. Transfusion- and community-acquired cytomegalovirus infection in children with malignant disease: A prospective study. Transfusion 37 (1997) 941-946
18. Huang E.S., Huong S.M., Tegtmeier G.E., et al. Cytomegalovirus: Genetic variation of viral genomes. Ann N Y Acad Sci 354 (1980) 332-346
19. Adler S.P. Transfusion-associated cytomegalovirus infections. Rev Infect Dis 5 (1983) 977-993
20. Stevens D.P., Barker L.F., Ketcham A.S., et al. Asymptomatic cytomegalovirus infection following blood transfusion in tumor surgery. JAMA 211 (1970) 1341-1344
21. Adler S.P., Baggett J., and McVoy M. Transfusion-associated cytomegalovirus infections in seropositive cardiac surgery patients. Lancet 2 (1985) 743-747
22. Winston D.J., Ho W.G., Howell C.L., et al. Cytomegalovirus infections associated with leukocyte transfusions. Ann Intern Med 93 (1980) 671-675
23. Hersman J., Meyers J.D., Thomas E.D., et al. The effect of granulocyte transfusions on the incidence of cytomegalovirus infection after allogeneic marrow transplantation. Ann Intern Med 96 (1982) 149-152
24. Meyers J.D., Flournoy N., and Thomas E.D. Risk factors for cytomegalovirus infection after human marrow transplantation. J Infect Dis 153 (1986) 478-488
25. Bowden R.A., Slichter S.J., Sayers M., et al. A comparison of filtered leukocyte-reduced and cytomegalovirus (CMV) seronegative blood products for the prevention of transfusion- associated CMV infection after marrow transplant. Blood 86 (1995) 3598-3603
26. Hillyer C.D., Emmens R.K., Zago-Novaretti M., et al. Methods for the reduction of transfusion-transmitted cytomegalovirus infection: Filtration versus the use of seronegative donor units. Transfusion 34 (1994) 929-934
27. Bowden R., and Sayers M. The risk of transmitting cytomegalovirus infection by fresh frozen plasma. Transfusion 30 (1990) 762-763
28. Diosi P., Moldovan E., and Tomescu N. Latent cytomegalovirus infection in blood donors. Br Med J 4 (1969) 660-662
29. Jordan M.C. Latent infection and the elusive cytomegalovirus. Rev Infect Dis 5 (1983) 205-215
30. Drew W.L., Tegtmeier G., Alter H.J., et al. Frequency and duration of plasma CMV viremia in seroconverting blood donors and recipients. Transfusion 43 (2003) 309-313
31. Ho M. Epidemiology of cytomegalovirus infections. Rev Infect Dis (1990) S701-S710 [12 Suppl 7]
32. Revello M.G., Zavattoni M., Sarasini A., et al. Human cytomegalovirus in blood of immunocompetent persons during primary infection: prognostic implications for pregnancy. J Infect Dis 177 (1998) 1170-1175
33. Zanghellini F., Boppana S.B., Emery V.C., et al. Asymptomatic primary cytomegalovirus infection: Virologic and immunologic features. J Infect Dis 180 (1999) 702-707
34. Roback J.D., Su L., Newman J.L., et al. Transfusion-transmitted cytomegalovirus (CMV) infections in a murine model: Characterization of CMV-infected donor mice. Transfusion 46 (2006) 889-895
35. Reddehase M.J., Podlech J., and Grzimek N.K. Mouse models of cytomegalovirus latency: Overview. J Clin Virol (2002) S23-S36 (25 Suppl 2)
36. Rawlinson W.D., Farrell H.E., and Barrell B.G. Analysis of the complete DNA sequence of murine cytomegalovirus. J Virol 70 (1996) 8833-8849
37. Bruggeman C.A., Li F., and Stals F.S. Pathogenicity: Animal models. Scand J Infect Dis Suppl 99 (1995) 43-50
38. Hanson L.K., Slater J.S., Karabekian Z., et al. Replication of murine cytomegalovirus in differentiated macrophages as a determinant of viral pathogenesis. J Virol 73 (1999) 5970-5980
39. Pollock J.L., Presti R.M., Paetzold S., et al. Latent murine cytomegalovirus infection in macrophages. Virology 227 (1997) 168-179
40. Cheung K.S., and Lang D.J. Transmission and activation of cytomegalovirus with blood transfusion: A mouse model. J Infect Dis 135 (1977) 841-845
41. Jordan C.T., Saakadze N., Newman J.L., et al. Photochemical treatment of platelet concentrates with amotosalen hydrochloride and ultraviolet A light inactivates free and latent cytomegalovirus in a murine transfusion model. Transfusion 44 (2004) 1159-1165
42. Reiser H., Kuhn J., Doerr H.W., et al. Human cytomegalovirus replicates in primary human bone marrow cells. J Gen Virol 67 (1986) 2595-2604 (Pt 12)
43. Bolovan-Fritts C.A., Mocarski E.S., and Wiedeman J.A. Peripheral blood CD14(+) cells from healthy subjects carry a circular conformation of latent cytomegalovirus genome. Blood 93 (1999) 394-398
44. Hahn G., Jores R., and Mocarski E.S. Cytomegalovirus remains latent in a common precursor of dendritic and myeloid cells. Proc Natl Acad Sci U S A 95 (1998) 3937-3942
45. von Laer D., Meyer-Koenig U., Serr A., et al. Detection of cytomegalovirus DNA in CD34+ cells from blood and bone marrow. Blood 86 (1995) 4086-4090
46. Mendelson M., Monard S., Sissons P., et al. Detection of endogenous human cytomegalovirus in CD34+ bone marrow progenitors. J Gen Virol 77 (1996) 3099-3102 (Pt 12)
47. Sindre H., Tjoonnfjord G.E., Rollag H., et al. Human cytomegalovirus suppression of and latency in early hematopoietic progenitor cells. Blood 88 (1996) 4526-4533
48. Soderberg-Naucler C., Fish K.N., and Nelson J.A. Reactivation of latent human cytomegalovirus by allogeneic stimulation of blood cells from healthy donors. Cell 91 (1997) 119-126
49. Soderberg-Naucler C., Fish K.N., and Nelson J.A. Interferon-gamma and tumor necrosis factor-alpha specifically induce formation of cytomegalovirus-permissive monocyte-derived macrophages that are refractory to the antiviral activity of these cytokines. J Clin Invest 100 (1997) 3154-3163
50. Lathey J.L., and Spector S.A. Unrestricted replication of human cytomegalovirus in hydrocortisone-treated macrophages. J Virol 65 (1991) 6371-6375
51. Ibanez C.E., Schrier R., Ghazal P., et al. Human cytomegalovirus productively infects primary differentiated macrophages. J Virol 65 (1991) 6581-6588
52. Slobedman B., and Mocarski E.S. Quantitative analysis of latent human cytomegalovirus. J Virol 73 (1999) 4806-4812
53. Roback J.D., Hillyer C.D., Drew W.L., et al. Multicenter evaluation of PCR methods for detecting CMV DNA in blood donors. Transfusion 41 (2001) 1249-1257
54. Roback J.D., Bray R.A., and Hillyer C.D. Longitudinal monitoring of WBC subsets in packed RBC units after filtration: implications for transfusion transmission of infections. Transfusion 40 (2000) 500-506
55. Roback J.D., Drew W.L., Laycock M.E., et al. CMV DNA is rarely detected in healthy blood donors using validated PCR assays. Transfusion 43 (2003) 314-321
56. Dumont L.J., Luka J., VandenBroeke T., et al. The effect of leukocyte-reduction method on the amount of human cytomegalovirus in blood products: A comparison of apheresis and filtration methods. Blood 97 (2001) 3640-3647
57. Payment P., and Trudel M. Isolation and identification of viruses. In: Payment P., and Trudel M. (Eds). Methods and techniques in virology (1993), Marcel Dekker, New York 33
58. Jordan M.C., and Mar V.L. Spontaneous activation of latent cytomegalovirus from murine spleen explants. J Clin Invest 70 (1982) 762-768
59. Olding L.B., Jensen F.C., and Oldstone M.B. Pathogenesis of cytomegalovirus infection. I. Activation of virus from bone marrow-derived lymphocytes by in vitro allogenic reaction. J Exp Med 141 (1975) 561-572
60. Rowe W.P., Hartley J.W., Waterman S., et al. Cytopathogenic agent resembling human salivary gland virus recovered from tissue cultures of human adenoids. Proc Soc Exp Biol Med 92 (1956) 418
61. Presti R.M., Pollock J.L., Dal Canto A.J., et al. Interferon gamma regulates acute and latent murine cytomegalovirus infection and chronic disease of the great vessels. J Exp Med 188 (1998) 577-588
62. Wu B.C., Dowling J.N., Armstrong J.A., et al. Enhancement of mouse cytomegalovirus infection during host-versus-graft reaction. Science 190 (1975) 56-58
63. Dowling J.N., Wu B.C., Armstrong J.A., et al. Enhancement of murine cytomegalovirus infection during graft-vs.-host reaction. J Infect Dis 135 (1977) 990-994
64. Hamilton J.D., and Seaworth B.J. Transmission of latent cytomegalovirus in a murine kidney tissue transplantation model. Transplantation 39 (1985) 290-296
65. Gilbert G.L., Hayes K., Hudson I.L., et al. Prevention of transfusion-acquired cytomegalovirus infection in infants by blood filtration to remove leucocytes. Neonatal Cytomegalovirus Infection Study Group. Lancet 1 (1989) 1228-1231
66. Verdonck L.F., de Graan-Hentzen Y.C., Dekker A.W., et al. Cytomegalovirus seronegative platelets and leukocyte-poor red blood cells from random donors can prevent primary cytomegalovirus infection after bone marrow transplantation. Bone Marrow Transplant 2 (1987) 73-78
67. Britt W.J., and Alford C.A. Cytomegalovirus. Fields virology (1996), Lippincott-Raven, Philadelphia 2493-2523
68. de Graan-Hentzen Y.C., Gratama J.W., Mudde G.C., et al. Prevention of primary cytomegalovirus infection in patients with hematologic malignancies by intensive white cell depletion of blood products. Transfusion 29 (1989) 757-760
69. De Witte T., Schattenberg A., Van Dijk B.A., et al. Prevention of primary cytomegalovirus infection after allogeneic bone marrow transplantation by using leukocyte-poor random blood products from cytomegalovirus-unscreened blood-bank donors. Transplantation 50 (1990) 964-968
70. Landaw E.M., Kanter M., and Petz L.D. Safety of filtered leukocyte-reduced blood products for prevention of transfusion-associated cytomegalovirus infection (letter). Blood 87 (1996) 4910
71. Bowden R.A., Slichter S., and Sayers M. Safety of filtered leukocyte-reduced blood products for prevention of transfusion-associated cytomegalovirus infection (response). Blood 87 (1996) 4910-4911
72. Nichols W.G., Price T.H., Gooley T., et al. Transfusion-transmitted cytomegalovirus infection after receipt of leukoreduced blood products. Blood 101 (2003) 4195-4200
73. Vamvakas E.C. Is white blood cell reduction equivalent to antibody screening in preventing transmission of cytomegalovirus by transfusion? A review of the literature and meta-analysis. Transfus Med Rev 19 (2005) 181-199
74. Corash L. Pathogen reduction technology: Methods, status of clinical trials, and future prospects. Curr Hematol Rep 2 (2003) 495-502
75. Lin L., Cook D.N., Wiesehahn G.P., et al. Photochemical inactivation of viruses and bacteria in platelet concentrates by use of a novel psoralen and long-wavelength ultraviolet light. Transfusion 37 (1997) 423-435
76. Lin L., Londe H., Janda J.M., et al. Photochemical inactivation of pathogenic bacteria in human platelet concentrates. Blood 83 (1994) 2698-2706
77. Hei D.J., Grass J., Lin L., et al. Elimination of cytokine production in stored platelet concentrate aliquots by photochemical treatment with psoralen plus ultraviolet A light. Transfusion 39 (1999) 239-248
78. Lin L. Inactivation of cytomegalovirus in platelet concentrates using Helinx technology. Semin Hematol 38 (2001) 27-33 (4 Suppl 11)
79. van Rhenen D., Gulliksson H., Cazenave J.P., et al. Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: The EuroSPRITE trial. Blood 101 (2003) 2426-2433